journal article·2025-08Open access

Ultrasound‐Propelled Nanomotors Enable Activatable Near‐Infrared‐II Fluorescence Imaging‐Guided Synergistic Oxygen‐Independent and Oxygen‐Dependent Sonodynamic Therapy of Atherosclerosis

Zeyu Jiang, Chuang Wei, Shanglang Cai, Qinrui Fu

Advanced Functional Materials· Volume 35· Issue 35

Abstract

Abstract Sonodynamic therapy (SDT) holds great promise as a therapeutic approach for treating atherosclerotic plaque. However, the therapeutic efficacy of SDT is hindered by the restricted tissue penetration depth and insufficient generation of reactive oxygen species (ROS) associated with conventional sonosensitizers. Furthermore, determining the optimal timing for ultrasound (US) irradiation after the administration of sonosensitizers presents a significant technical challenge. Addressing these issues is crucial for enhancing the effectiveness of SDT. Herein, a hyaluronic acid‐modified US‐propelled Janus mesoporous SiO2 partially coated gold nanorods loaded with 2,2‐azobis[2‐(2‐imidazolin‐2‐yl) propane] dihydrochloride (AIPH) is developed, along with functionalized Ag/Ag2S nanoparticles (HA‐JASAA), for near‐infrared‐II (NIR‐II) fluorescence imaging‐guided SDT of atherosclerotic plaque. Following intravenous administration of HA‐JASAA, the hyaluronic acid modification enables specific targeting of proinflammatory macrophages within atherosclerotic plaques. Subsequently, upon reacting with H2O2 in the atherosclerotic microenvironment, it turns on the NIR‐II fluorescence signal. US irradiation is applied when the intensity of NIR‐II fluorescence signal reaches its peak; AIPH loaded in HA‐JASAA undergoes conversion into nitrogen propelling the HA‐JASAA toward deep penetration into plaque tissue. Furthermore, under US activation, two sonosensitizers, AIPH and Ag2S, generate oxygen‐independent and oxygen‐dependent ROS respectively to induce apoptosis of lesional macrophages, thereby significantly inhibiting the progression of atherosclerotic plaque.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Anesthesia and Neurotoxicity Research · Photoacoustic and Ultrasonic Imaging · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

The Affiliated Hospital of Qingdao University Institute of Chronic Disease College of Medicine Qingdao University Qingdao 266021 China

Department of Cardiovascular Medicine The Affiliated Hospital of Qingdao University College of Medicine Qingdao University Qingdao 266021 China

Funding

Natural Science Foundation of Qingdao Municipality · Natural Science Foundation of Shanghai Municipality · Taishan Scholar Project of Shandong Province

References (43)

Show source-provided references
1. 10.1016/j.jacc.2022.11.00510.1016/j.jacc.2022.11.005 ↗
2. 10.1016/j.jacc.2019.10.00910.1016/j.jacc.2019.10.009 ↗
3. 10.1038/s41572-019-0106-z10.1038/s41572-019-0106-z ↗
4. 10.1093/eurheartj/ehab60010.1093/eurheartj/ehab600 ↗
5. 10.1016/j.cell.2022.04.00410.1016/j.cell.2022.04.004 ↗
6. 10.1161/CIRCRESAHA.118.31137810.1161/CIRCRESAHA.118.311378 ↗
7. 10.1038/s41577-021-00584-110.1038/s41577-021-00584-1 ↗
8. 10.1161/CIRCULATIONAHA.117.03048410.1161/CIRCULATIONAHA.117.030484 ↗
9. 10.1124/pr.118.01717810.1124/pr.118.017178 ↗
10. 10.1038/s41419-023-06206-z10.1038/s41419-023-06206-z ↗
11. 10.1038/s42255-019-0154-410.1038/s42255-019-0154-4 ↗
12. 10.1016/j.nantod.2021.10135110.1016/j.nantod.2021.101351 ↗
13. 10.1038/s41569-021-00629-x10.1038/s41569-021-00629-x ↗
14. 10.1016/j.bioactmat.2022.02.02210.1016/j.bioactmat.2022.02.022 ↗
15. 10.1002/adma.20240966310.1002/adma.202409663 ↗
16. 10.1039/C9CS00648F10.1039/C9CS00648F ↗
17. 10.1002/adfm.20230254110.1002/adfm.202302541 ↗
18. 10.1002/adhm.20210194610.1002/adhm.202101946 ↗
19. 10.1016/j.jconrel.2023.08.00310.1016/j.jconrel.2023.08.003 ↗
20. 10.1093/cvr/cvy13910.1093/cvr/cvy139 ↗
21. 10.1007/s12274-023-6156-210.1007/s12274-023-6156-2 ↗
22. 10.1021/acsnano.2c0217710.1021/acsnano.2c02177 ↗
23. 10.1002/advs.20220241610.1002/advs.202202416 ↗
24. 10.1186/s12951-020-00744-w10.1186/s12951-020-00744-w ↗
25. 10.1038/s41586-023-06017-410.1038/s41586-023-06017-4 ↗
26. 10.1021/acsnano.7b0138510.1021/acsnano.7b01385 ↗
27. 10.1016/j.carbpol.2019.11578710.1016/j.carbpol.2019.115787 ↗
28. 10.1016/j.carbpol.2022.11963210.1016/j.carbpol.2022.119632 ↗
29. 10.1002/anie.20201368910.1002/anie.202013689 ↗
30. 10.1002/adfm.20170611710.1002/adfm.201706117 ↗
31. 10.1038/s41565-024-01681-710.1038/s41565-024-01681-7 ↗
32. 10.1093/eurheartj/ehad655.327310.1093/eurheartj/ehad655.3273 ↗
33. 10.1002/adfm.20221465510.1002/adfm.202214655 ↗
34. 10.1021/jacs.3c0498110.1021/jacs.3c04981 ↗
35. 10.1002/advs.20220706610.1002/advs.202207066 ↗
36. 10.1002/adfm.20200177110.1002/adfm.202001771 ↗
37. 10.1021/nl801618710.1021/nl8016187 ↗
38. 10.1021/acs.nanolett.1c0019710.1021/acs.nanolett.1c00197 ↗
39. 10.1002/adma.20211066010.1002/adma.202110660 ↗
40. 10.1039/C9NR05733A10.1039/C9NR05733A ↗
41. 10.1039/C8NH00340H10.1039/C8NH00340H ↗
42. 10.1146/annurev.immunol.021908.13262010.1146/annurev.immunol.021908.132620 ↗
43. 10.1038/nri267510.1038/nri2675 ↗